Supporting Information for

Synthesis of Spiro-3*H*-indazoles via [3+2] Dipolar Cycloaddition of Arynes with 6-Diazocyclohex-2-en-1-one Derivatives and

Fused-2H-indazoles by Subsequent Rearrangement

Bin Cheng,^{*a} Bian Bao,^a Bing Zu,^a Xiaoguang Duan,^a Shengguo Duan,^a Yun Li^a and Hongbin Zhai*^{abc}

^{a.} State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China. E-mail: chengb@lzu.edu.cn

^{b.} Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School of Peking University, Shenzhen 518055, China. E-mail: zhaihb@pkusz.edu.cn

^{c.} Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300071, China

List of contents

1. General	•••••• S2
2. General Experimental Procedure	····· \$2-\$3
3. Proposed Mechanisms for the Formation of Spiro-3H-indazoles and Fused-2H-indazoles	····· \$3
4. References ·····	•••••• S4
5. Characterization Data of Products	····· \$5-\$9
6. NMR spectra ·····	·····S10-S30

1. General

All isolated compounds were characterized on Varian 300, Bruker 400, JEOL 400 MHz spectrometers in CDCl₃, (CD₃)₂CO or CD₃OD. Chemical shifts were reported as δ values relative to internal CHCl₃ (δ 7.26 for ¹H NMR and 77.16 for ¹³C NMR), (CH₃)₂CO (δ 2.05 for ¹H NMR and δ 29.84 for ¹³C NMR) and MeOH (δ 3.31 for ¹H NMR and 49.15 for ¹³C NMR). High-resolution mass spectra (HRMS) were obtained on a 4G mass spectrometer by using electrospray ionization (ESI) analyzed by quadrupole time-of- flight (QTof). All melting points were measured with the samples after column chromatography and uncorrected. Column chromatography was performed on silica gel. Anhydrous THF and toluene were distilled over sodium benzophenone ketyl under Ar. All other solvents and reagents were used as obtained from commercial sources without further purification.

2. General Experimental Procedure

General Procedure for the Preparation of 6-Diazocyclohex-2-en-1-one Derivatives

1a and **1c** were prepared according to the literature.¹ **1b** and **1d–u** were prepared according to the literature.²

General Procedure for the Preparation of 3d-t.



To a solution of diazo compound **1d** (52 mg, 0.30 mmol) and benzyne precursor **2a** (134 mg, 0.450 mmol, 1.5 equiv) in THF (3.0 mL) was added TBAT (243 mg, 0.450 mmol, 1.5 equiv) at 0 $^{\circ}$ C. Then the mixture was warmed to room temperature. After **1d** was completely depleted monitoring on TLC, the solvent was removed and the resulting residue was purified by flash column chromatography (PE:EA = 10:1) to give **3d** (69 mg, 93%) as a white solid.

3e-t were prepared following a similar method. Conditions: **1** (0.30 mmol), **2** (0.45 mmol, 1.5 equiv), TBAT (0.45 mmol, 1.5 equiv), solvent (3 mL), 0 to 20 °C, air.

Procedure for the Preparation of Fused-2H-indazole 4e-u

A solution of **3e** (48 mg, 0.24 mmol) in PhMe (2.4 mL) was heated to 110 $^{\circ}$ C and kept for 12 h. The solvent was removed under reduced pressure and the resulting residue was purified by flash chromatography (PE:EA = 1:2) to give **4e** (27 mg, 56%) as a light yellow oil.

$$1) \frac{2a}{15 \text{ equiv}} \xrightarrow{\text{O}}_{\text{DAT. THF}} \xrightarrow{\text{O}}_{\text{N}_2} \xrightarrow{\text{O}}_{\text{21 TFA, CHCl}_3} \xrightarrow{\text{O}}_{\text{81\% (2 steps)}} \xrightarrow{\text{O}}_{\text{4d}} \xrightarrow{\text{Ad}}$$

To a solution of diazo compound **1d** (52 mg, 0.30 mmol) and benzyne precursor **2a** (134 mg, 0.450 mmol, 1.5 equiv) in THF (3.0 mL) was added TBAT (243 mg, 0.450 mmol, 1.5 equiv) at 0 $^{\circ}$ C. Then the mixture was warmed to room temperature. After **1d** was completely depleted monitoring on TLC, the solvent was removed, and the resulting residue was redissolved in TFA/CHCl₃ (1 M, 1.0 mL) at room temperature and the solution was stirred for 5 min. After full conversion, the solvent was removed under reduced pressure and the resulting residue was purified by flash column chromatography (EA) to give **4d** (60 mg, 81% for two steps) as a light

yellow oil.

To a solution of diazo compound **1s** (59 mg, 0.32 mmol) and benzyne precursor **2a** (143 mg, 0.479 mmol, 1.5 equiv) in THF (3.2 mL) was added TBAT (259 mg, 0.480 mmol, 1.5 equiv) at 0 $^{\circ}$ C. Then the mixture was warmed to room temperature. After **1s** was completely depleted monitoring on TLC, the solvent was removed and the resulting residue was passed through a short silica gel column to get the crude spiro indazole **3s**. Then the crude product was redissolved in DCM (3 mL) and added SiO₂ (200 mg). The solution was stirred at room temperature. After full conversion, the solvent was removed under reduced pressure and the resulting residue was purified by flash column chromatography (PE:EA = 1:1) to give **4s** (42 mg, 50% for two steps) as a yellow oil.



To a solution of diazo compound **1u** (75 mg, 0.20 mmol) and benzyne precursor **2a** (89 mg, 0.30 mmol, 1.5 equiv) in THF (2.0 mL) was added TBAT (162 mg, 0.300 mmol, 1.5 equiv) at 0 °C. Then the mixture was warmed to room temperature. After **1u** was completely depleted monitoring on TLC, the solvent was removed and the resulting residue was passed through a short silica gel column to get the crude spiro indazole **3u**. Then the crude product was redissolved in CHCl₃ (2 mL) and added SiO₂ (125 mg). The solution was stirred at room temperature. After full conversion, the solvent was removed under reduced pressure and the resulting residue was purified by flash column chromatography (PE:EA = 1:2) to give **4u** (78 mg, 88% for two steps) as a yellow oil. **Procedure for the Preparation of 5d**

$$\begin{array}{c} & & \\$$

To a solution of spiroindazole **3d** (19 mg, 0.080 mmol) in DCM/MeOH (2.0 mL, 10:1) was added NaBH₄ (ca. 5.0 mg, 0.13 mmol, 1.6 equiv) at room temperature. After the solution was stirred for 15 min, excess CH_3COCH_3 was added. Then the solvent was removed and the resulting residue was purified by flash column chromatography (EA) to give **5d** (13 mg, 68%) as a white solid. **3. Proposed Mechanisms for the Formation of Spiro-3***H***-indazoles and Fused-2***H***-indazoles The mechanisms were proposed according to the literature.³**



4. References

1. Y. Jiang, V. Z. Y. Khong, E. Lourdusamya and C.-M. Park, Chem. Comm., 2012, 48, 3133.

2. L. Zhao, J. Wang, H. Zheng, Y. Li, K.Yang, B. Cheng, X. Jin, X. Yao and H. Zhai, *Org. Lett.*, 2014, **16**, 6378.

3. (a) M. P. Sammes and A. R. Katritzky, *Adv. Heterocycl. Chem.*, 1983, 34, 1; (b) Z. Liu, F. Shi, P. D. G. Martinez, C. Raminelli and R. C. Larock, *J. Org. Chem.*, 2008, 73, 219; (c) D. Vuluga, J. Legros, B. Crousse and D. Bonnet-Delpon, *Green Chem.*, 2009, 11, 156.

5. Characterization Data of Products.



3d (69 mg, Y = 93%, $R_f = 0.5$ (PE:EA = 5:1)) was isolated as a white solid; mp 107–108 °C. ¹H NMR (400 MHz, (CD₃)₂CO) δ 8.21 (d, *J* = 7.6 Hz, 1H), 7.94 (dd, *J* = 7.6, 0.6 Hz, 1H), 7.71 (td, *J* = 7.6, 1.2 Hz, 1H), 7.66–7.62 (m, 2H), 7.57–7.53 (m, 2H), 7.44 (t, *J* = 7.2 Hz, 1H), 3.75–3.68 (m, 1H), 3.42–3.34 (m, 1H), 2.69–2.62 (m, 1H), 2.53–2.46 (m, 1H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 189.3, 159.2, 145.4, 142.5, 135.3, 132.8, 130.9, 130.4, 130.4, 128.6, 127.9, 123.7, 122.4, 101.5, 32.2, 27.6; ESI-HRMS *m*/*z* calcd for C₁₆H₁₃N₂O [M + H]⁺ 249.1022, found 249.1021.



3e (47 mg, Y = 79%, $R_f = 0.3$ (PE:EA = 2:1)) was isolated as a white solid; mp 98–99 °C. ¹H NMR (300 MHz, CDCl₃) 8.17 (d, *J* = 7.5 Hz, 1H), 7.59–7.53 (m, 1H), 7.52–7.45 (m, 2H), 7.41–7.35 (m, 1H), 6.36 (dt, *J* = 10.2, 2.1 Hz, 1H), 3.15–3.02 (m, 1H), 2.81–2.69 (m, 1H), 2.50–2.42 (m, 1H), 2.38–2.29 (m, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 189.3, 158.0, 152.1, 140.4, 130.2, 129.6, 122.4, 122.2, 99.8, 31.0, 24.9; ESI-HRMS *m*/*z* calcd for C₁₂H₁₁N₂O [M + H]⁺ 199.0866, found 199.0864.



3f (64 mg, Y = 80%, $R_f = 0.7$ (PE:EA = 2:1)) was isolated as a white solid; mp 99–100 °C. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.23–8.20 (m, 1H), 7.69–7.63 (m, 3H), 7.60–7.48 (m, 3H), 3.75–3.65 (m, 1H), 3.43–3.34 (m, 1H), 2.75–2.65 (m, 1H), 2.52–2.44 (m, 1H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 188.7, 162.4 (d, *J* = 243.7 Hz), 159.3, 142.2, 141.6 (d, *J* = 2.3 Hz), 134.3 (d, *J* = 6.0 Hz), 132.8 (d, *J* = 7.5 Hz), 131.1, 130.5, 123.8, 122.7 (d, *J* = 21.8 Hz), 122.5, 113.9 (d, *J* = 21.8 Hz), 101.1, 32.3, 27.1; ESI-HRMS *m/z* calcd for C₁₆H₁₂FN₂O [M + H]⁺ 267.0928, found 267.0927.



3g (65 mg, Y = 78%, $R_f = 0.5$ (PE:EA = 2:1)) was isolated as a yellow oil. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.20–8.17 (m, 1H), 7.90 (d, *J* = 8.7 Hz, 1H), 7.65–7.61 (m, 1H), 7.61–7.58 (m, 1H), 7.55–7.50 (m, 1H), 7.06 (d, *J* = 2.4 Hz, 1H), 6.98 (dd, *J* = 8.7, 2.4 Hz, 1H), 3.95 (s, 3H), 3.72–3.62 (m, 1H), 3.39–3.29 (m, 1H), 2.63–2.44 (m, 2H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 187.6, 165.4, 159.2, 148.0, 142.8, 131.1, 130.8, 130.2, 126.2, 123.6, 122.3, 114.9, 113.7, 101.3, 56.1, 32.2, 27.9; ESI-HRMS *m*/*z* calcd for C₁₇H₁₅N₂O₂ [M + H]⁺ 279.1128, found 279.1129.



3h (93 mg, Y = 95%, $R_f = 0.15$ (DCM:PE = 1:1)) was isolated as a white solid; mp 103–104 °C. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.21 (d, *J* = 8.4 Hz, 1H), 8.04 (d, *J* = 2.4 Hz, 1H), 7.86 (dd, *J* = 8.1, 2.1 Hz, 1H), 7.69–7.64 (m, 2H), 7.59–7.54 (m, 2H), 3.74–3.63 (m, 1H), 3.41–3.32 (m, 1H), 2.76–2.67 (m, 1H), 2.51–2.43 (m, 1H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 188.4, 159.3, 144.6, 142.1, 137.9, 134.4, 132.7, 131.1, 130.8, 130.5, 123.8, 122.5, 121.2, 101.1, 32.0, 27.3; ESI-HRMS *m*/*z* calcd For C₁₆H₁₂BrN₂O [M + H]⁺ 327.0128, found 327.0132.



3i (51 mg, Y = 68%, $R_f = 0.9$ (DCM:EA = 30:1)) was isolated as a white solid; mp 112–113 °C. ¹H NMR (300 MHz, CDCl₃) δ 8.24 (d, J = 7.8 Hz, 1H), 7.95 (dd, J = 7.8, 1.2 Hz, 1H), 7.69–7.59 (m, 2H), 7.50–7.40 (m, 2H), 7.26–7.13 (m, 2H), 5.07 (d, J = 11.7 Hz, 1H), 4.45 (d, J = 11.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 183.2, 161.7, 158.7, 137.3, 137.2, 130.7, 130.4, 128.4, 122.8, 122.6, 122.6, 120.4, 118.5, 97.4, 70.8; ESI-HRMS *m*/*z* calcd for C₁₅H₁₁N₂O₂ [M + H]⁺ 251.0815, found 251.0816.



3j (55 mg, Y = 87%, $R_f = 0.6$ (PE:EA = 2:1)) was isolated as a white solid; mp 112–113 °C. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.16–8.13 (m, 1H), 7.63–7.58 (m, 2H), 7.55–7.50 (m, 1H), 6.14–6.12 (m, 1H), 3.05–2.94 (m, 1H), 2.83–2.73 (m, 1H), 2.49–2.41 (m, 1H), 2.38–2.30 (m, 1H), 2.21 (s, 3H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 189.1, 166.1, 159.0, 142.3, 130.7, 130.2, 126.4, 123.5, 122.2, 100.2, 31.2, 30.1, 24.5; ESI-HRMS *m*/*z* calcd for C₁₃H₁₂N₂O + H⁺ [M + H]⁺ 213.1022, found 213.1021.



3k (45 mg, Y = 66%, $R_f = 0.5$ (PE:EA = 2:1)) was isolated as a red solid; mp 102–103 °C. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.14 (dd, *J* = 7.5, 0.6 Hz, 1H), 7.64–7.58 (m, 2H), 7.55–7.51 (m, 1H), 5.66 (s, 1H), 3.91 (s, 3H), 3.05–2.94 (m, 1H), 2.83–2.73 (m, 1H), 2.49–2.30 (m, 2H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 188.6, 180.0, 159.2, 142.8, 130.6, 130.1, 123.4, 122.2, 103.0, 100.3, 56.8, 29.9, 27.9; ESI-HRMS *m*/*z* calcd for C₁₃H₁₃N₂O₂ [M + H]⁺ 229.0972, found 229.0971.



31 (60 mg, Y = 88%, $R_f = 0.25$ (PE:EA = 5:1)) was isolated as a white solid; mp 68–69 °C. ¹H NMR (400 MHz, (CD₃)₂CO) δ 8.17–8.15 (m, 1H), 7.66–7.64 (m, 1H), 7.63–7.55 (m, 2H), 7.21 (d, *J* = 10.4 Hz, 1H), 6.16 (d, *J* = 10.0 Hz, 1H), 2.84 (d, *J* = 14.4 Hz, 1H), 1.72 (dd, *J* = 14.4, 2.0 Hz, 1H), 1.60 (s, 3H), 1.33 (s, 3H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 189.6, 162.0, 159.3, 143.7, 130.9, 130.0, 126.9, 123.8, 122.1, 102.4, 45.2, 34.7, 31.1, 29.0; ESI-HRMS *m*/*z* calcd for C₁₄H₁₅N₂O [M + H]⁺ 227.1179, found 227.1176.



3m-a (32 mg, Y = 42%, $R_f = 0.35$ (PE:EA = 5:1), with low polarity) was isolated as a colorless oil. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.12–8.09 (m, 1H), 7.66–7.63 (m, 1H), 7.58–7.54 (m, 2H), 7.33–7.30 (m, 1H), 4.63–4.60 (m, 1H), 4.50–4.47 (m, 1H), 3.83–3.76 (m, 1H), 3.52–3.39 (m, 1H), 2.80–2.68 (m, 1H), 1.83–1.81(m, 3H), 1.25–1.24 (m, 3H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 190.0, 160.6, 148.0, 143.8, 141.7, 136.1, 130.3, 129.9, 124.9, 121.9, 114.7, 106.4, 51.5, 32.0, 22.0, 16.5; ESI-HRMS *m*/*z* calcd for C₁₆H₁₇N₂O [M + H]⁺ 253.1335, found 253.1333.



3m-b (30 mg, Y = 39%, $R_f = 0.25$ (PE:EA = 5:1), with high polarity) was isolated as a colorless oil. ¹H NMR (300 MHz, (CD₃)₂CO) δ 8.14–8.11 (m, 1H), 7.64–7.58 (m, 2H), 7.52–7.47 (m, 1H), 7.28–7.24 (m, 1H), 4.54–4.52 (m, 1H), 4.32 (br s, 1H), 4.12–4.07 (m, 1H), 3.09–2.96 (m, 1H), 2.87–2.75 (m, 1H), 1.82–1.80 (m, 3H), 1.38–1.36 (m, 3H); ¹³C NMR (75 MHz, (CD₃)₂CO) δ 189.6, 159.2, 147.5, 143.0, 138.4, 134.9, 130.5, 130.4, 124.1, 122.4, 114.4, 102.7, 48.4, 30.3, 23.0, 16.3; ESI-HRMS *m/z* calcd for C₁₆H₁₇N₂O [M + H]⁺ 253.1335, found 253.1334.



3n (71 mg, Y = 86%, $R_f = 0.24$ (PE:EA = 5:1)) was isolated as a white solid; mp 140–141 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 7.6 Hz, 1H), 7.95 (s, 1H), 7.61 (t, J = 7.2 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 7.16 (s, 1H), 3.75–3.67 (m, 1H), 3.34–3.27 (m, 1H), 2.60–2.54 (m, 1H), 2.48–2.41 (m, 1H), 2.38 (s, 3H), 2.31 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 189.3, 157.5, 144.1, 139.7, 139.1, 138.5, 134.5, 132.1, 129.3, 128.6, 127.2, 123.4, 122.8, 99.7, 31.9, 27.2, 20.5, 20.3; ESI-HRMS m/z calcd for C₁₈H₁₇N₂O [M + H]⁺ 277.1335, found 277.1336.



30 (70 mg, Y = 80%, $R_f = 0.40$ (PE:EA = 3:1)) was isolated as a light yellow solid; mp 189–190 °C.

¹H NMR (400 MHz, (CD₃)₂CO) 7.93 (dd, J = 7.6, 0.8 Hz, 1H), 7.71–7.67 (m, 1H), 7.62 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.48–7.41 (m, 1H), 7.14 (s, 1H), 6.21 (br s, 1H), 6.21 (br s, 1H), 3.79–3.71 (m, 1H), 3.40–3.25 (m, 1H), 2.84–2.75 (m, 1H), 2.31–2.25 (m, 1H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 189.4, 154.5, 151.6, 150.1, 145.6, 139.3, 135.2, 134.0, 133.1, 130.4, 128.5, 127.8, 104.0, 102.3, 101.1, 32.8, 28.0; ESI-HRMS *m*/*z* calcd for C₁₇H₁₃N₂O₃ [M + H]⁺ 293.0921, found 293.0918.



3p (65 mg, Y = 70%, $R_f = 0.15$ (PE:EA = 3:1)) was isolated as a light yellow solid; mp 178–179 °C. ¹H NMR (400 MHz, (CD₃)₂CO) δ 7.93 (d, *J* = 8.0 Hz, 1H), 7.74 (s, 1H), 7.70–7.66 (m, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.29 (s, 1H), 3.97 (s, 3H), 3.85 (s, 3H), 3.81–3.71 (m, 1H), 3.35–3.29 (m, 1H), 2.82–2.75 (m, 1H), 2.26–2.20 (m, 1H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 189.8, 153.5, 152.8, 151.4, 145.6, 136.9, 135.1, 133.2, 130.3, 128.5, 127.8, 106.2, 104.7, 101.5, 56.5, 56.5, 32.9, 28.0; ESI-HRMS *m*/*z* calcd for C₁₈H₁₇N₂O₃ [M + H]⁺ 309.1234, found 309.1233.



3q (77 mg, Y = 92%, $R_f = 0.35$ (PE:EA = 3:1)) was isolated as a yellow solid; mp 118–119 °C. ¹H NMR (400 MHz, (CD₃)₂CO) δ 7.94 (dd, J = 7.8, 0.8 Hz, 1H), 7.70 (td, J = 7.6, 1.2 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.50–7.43 (m, 2H), 7.19 (d, J = 8.0 Hz, 1H), 7.13 (dd, J = 7.2, 0.4 Hz 1H), 4.17 (s, 3H), 3.75–3.67 (m, 1H), 3.40–3.33 (m, 1H), 2.68–2.61 (m, 1H), 2.49–2.42 (m, 1H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 189.8, 154.3, 148.5, 146.0, 145.9, 135.8, 133.4, 133.4, 130.9, 129.1, 128.4, 116.0, 114.7, 101.8, 57.9, 32.9, 28.0; ESI-HRMS *m*/*z* calcd for C₁₇H₁₅N₂O₂ [M + H]⁺ 279.1128, found 279.1130.

4d (60 mg, Y = 81% for two steps, $R_f = 0.45$ (PE:EA = 2:1)) was isolated as a light yellow oil. ¹H NMR (400 MHz, (CD₃)₂CO) δ 7.98 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.52–7.44 (m, 2H), 7.40–7.38 (m, 1H), 7.35–7.31 (m, 2H), 7.08 (t, *J* = 7.2, 1H), 3.52–3.48 (m, 2H), 3.32–3.28 (m, 2H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 169.1, 146.3, 144.5, 142.3, 132.8, 132.1, 131.7, 130.9, 127.0, 126.9, 123.0, 121.1, 120.5, 110.8, 34.8, 30.0; ESI-HRMS *m/z* calcd for C₁₆H₁₃N₂O [M + H]⁺ 249.1022, found 249.1023.



4e (27 mg, Y = 56%, $R_f = 0.43$ (PE:EA = 1:1)) was isolated as a light yellow oil. ¹H NMR (300

MHz, CDCl₃) δ 7.68 (d, J = 9.0 Hz, 1H), 7.49 (d, J = 8.7 Hz, 1H), 7.32–7.27 (m, 1H), 7.07–7.01 (m, 1H), 6.99–6.93 (m, 1H), 6.45 (dt, J = 12.3, 1.5 Hz, 1H), 3.43–3.39 (m, 2H), 2.74–2.68 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 163.6, 150.2, 148.2, 136.4, 129.6, 125.5, 123.5, 121.0, 120.5, 119.3, 27.0, 23.3; ESI-HRMS *m*/z calcd for C₁₂H₁₁N₂O [M + H]⁺ 199.0866, found 199.0865.



4s (42 mg, Y = 50% for two steps, $R_f = 0.1$ (PE:EA = 5:1)) was isolated as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, *J* = 7.6, 1.2 Hz, 1H), 7.74 (d, *J* = 9.2 Hz, 1H), 7.61 (dt, *J* = 8.8, 1.2 Hz, 1H), 7.51 (d, *J* = 8.4 Hz, 1H), 7.45 (dt, *J* = 8.8, 1.2 Hz, 1H), 7.35–7.31 (m, 1H), 7.27–7.26 (m, 1H), 7.06–7.02 (m, 1H), 2.91 (br s, 2H), 2.70 (t, *J* = 6.4 Hz, 2H), 2.00–1.94 (m, 2H); ¹³C NMR (100 MHz, (CD₃)₂CO) δ 166.6, 150.9, 139.8, 139.1, 135.1, 134.5, 132.6, 130.4, 130.3, 127.9, 123.8, 122.2, 122.0, 119.6, 32.1, 31.6, 21.9; ESI-HRMS *m*/*z* calcd for C₁₇H₁₅N₂O [M + H]⁺ 263.1179, found 263.1178.



4u (78 mg, Y = 88% for two steps, $R_f = 0.40$ (PE:EA = 1:1)) was isolated as a yellow oil. ¹H NMR (300 MHz, CDCl₃) δ 7.69 (d, J = 8.7 Hz, 1H), 7.49 (d, J = 8.7 Hz, 1H), 7.32–7.27 (m, 1H), 7.08–7.03 (m, 1H), 6.28 (s, 1H), 4.63 (t, J = 8.1 Hz, 1H), 3.59 (d, J = 15.0 Hz, 1H), 3.12 (d, J = 15.0 Hz, 1H), 2.58–2.39 (m, 2H), 2.34 (q, J = 7.5 Hz, 2H), 2.27–2.14 (m, 1H), 1.96–1.81 (m, 3H), 1.74–1.49 (m, 4H), 1.45–1.33 (m, 1H), 1.30–1.06 (m, 3H), 1.15 (t, J = 7.5 Hz, 4H), 1.01 (s, 3H), 0.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 174.5, 169.8, 163.2, 150.2, 133.2, 129.2, 123.4, 122.3, 120.1, 119.3, 119.2, 82.1, 51.8, 50.5, 43.5, 42.6, 36.8, 36.6, 35.6, 33.7, 31.8, 27.8, 27.7, 23.5, 21.7, 18.7, 12.2, 9.3; ESI-HRMS *m*/*z* calcd for C₂₈H₃₅N₂O₃ [M + H]⁺ 447.2642, found 447.2641.



5d (13 mg, Y = 68%, $R_f = 0.5$ (PE:EA = 1:1)) was isolated as a white solid; mp 132–133 °C. ¹H NMR (400 MHz, CD₃OD) δ 7.62 (d, *J* = 8.0 Hz, 1H), 7.45 (d, *J* = 8.4 Hz, 1H), 7.35–7.31 (m, 2H), 7.17–7.15 (m, 3H), 7.06 (t, *J* = 7.2 Hz, 1H), 4.63 (s, 2H), 3.28–3.24 (m, 2H), 3.17–3.13 (m, 2H); ¹³C NMR (100 MHz, CD₃OD) δ 147.2, 142.8, 141.1, 140.1, 130.7, 129.7, 128.9, 127.9, 127.5, 123.1, 121.3, 121.3, 111.2, 63.2, 33.4, 29.9; ESI-HRMS *m*/*z* calcd for C₁₆H₁₇N₂O [M + H]⁺ 253.1335, found 253.1334.

6. NMR spectra



Fig. S2. 13 C and DEPT-135 NMR of compound 3d (100 MHz, (CD₃)₂CO).



Fig. S4. ¹³C NMR of compound **3e** (75 MHz, CDCl₃).



Fig. S6. 13 C and DEPT-135 NMR of compound 3f (75 MHz, (CD₃)₂CO).



Fig. S8. ¹³C NMR of compound **3g** (75 MHz, (CD₃)₂CO).



Fig. S10. 13 C NMR of compound 3h (75 MHz, (CD₃)₂CO).



Fig. S12. ¹³C NMR of compound 3i (75 MHz, CDCl₃).





Fig. S14. 13 C NMR of compound 3j (75 MHz, (CD₃)₂CO).



Fig. S15. 13 C and DEPT-135 NMR of compound 3j (75 MHz, (CD₃)₂CO)



Fig. S16. 1 H NMR of compound 3k (300 MHz, (CD₃)₂CO).



Fig. S17. 13 C and DEPT-135 NMR of compound 3k (75 MHz, (CD₃)₂CO).



Fig. S18. ¹H NMR of compound **31** (400 MHz, (CD₃)₂CO).



Fig. S19. 13 C and DEPT-135 NMR of compound 3l (100 MHz, (CD₃)₂CO).



Fig. S20. ¹H NMR of compound 3m-a (300 MHz, (CD₃)₂CO).



Fig. S21. ¹³C NMR of compound **3m-a** (75 MHz, (CD₃)₂CO).



Fig. S22. 1 H NMR of compound 3m-b (300 MHz, (CD₃)₂CO).



Fig. S23. 13 C NMR of compound 3m-b (75 MHz, (CD₃)₂CO).



Fig. S24. ¹H NMR of compound 3n (400 MHz, CDCl₃).



Fig. S26. ¹H NMR of compound **30** (400 MHz, (CD₃)₂CO).



Fig. S27. ^{13}C NMR of compound 30 (100 MHz, (CD₃)₂CO).



Fig. S28. 1 H NMR of compound 3p (400 MHz, (CD₃)₂CO).



Fig. S30. 1 H NMR of compound 3q (400 MHz, (CD₃)₂CO).





Fig. S32. ¹H NMR of compound **4d** (400 MHz, (CD₃)₂CO).



Fig. S33. 13 C and DEPT-135 NMR of compound 4d (100 MHz, (CD₃)₂CO).



Fig. S34. ¹H NMR of compound 4e (300 MHz, CDCl₃).



Fig. S36. ¹H NMR of compound 4s (400 MHz, CDCl₃).



Fig. S37. 13 C and DEPT-135 NMR of compound 4s (100 MHz, (CD₃)₂CO).



Fig. S38. ¹H NMR of compound **4u** (300 MHz, CDCl₃).



Fig. S40. 1 H NMR of compound 5d (400 MHz, CD₃OD).



Fig. S41. 13 C and DEPT-135 NMR of compound 5d (100 MHz, CD₃OD).